Literature DB >> 24474554

Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?

Vinay Prasad1, Andrae Vandross.   

Abstract

Mesh：

Year:  2014        PMID： 24474554     DOI： 10.1007/s00432-014-1590-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  23 in total

1.  Medical reversal: why we must raise the bar before adopting new technologies.

Authors:  Vinay Prasad; Adam Cifu
Journal:  Yale J Biol Med       Date:  2011-12

2.  Progression-free survival: meaningful or simply measurable?

Authors:  Christopher M Booth; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

Review 3.  Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.

Authors:  Rajeshwari Sridhara; John R Johnson; Robert Justice; Patricia Keegan; Aloka Chakravarty; Richard Pazdur
Journal:  J Natl Cancer Inst       Date:  2010-01-29       Impact factor: 13.506

Review 4.  Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.

Authors:  David Lebwohl; Andrea Kay; William Berg; Jean Francois Baladi; Ji Zheng
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360

5.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Authors:  Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; Thomas E Hutson; M Dror Michaelson; Vera A Gorbunova; Martin E Gore; Igor G Rusakov; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; Ho Yeong Lim; Hirotsugu Uemura; Jamal Tarazi; David Cella; Connie Chen; Brad Rosbrook; Sinil Kim; Robert J Motzer
Journal:  Lancet       Date:  2011-11-04       Impact factor: 79.321

Review 6.  Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points.

Authors:  A Kay; J Higgins; A G Day; R M Meyer; C M Booth
Journal:  Ann Oncol       Date:  2011-11-02       Impact factor: 32.976

7.  Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials.

Authors:  J P Ioannidis
Journal:  JAMA       Date:  1998-01-28       Impact factor: 56.272

8.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

9.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Authors:  Robert J Motzer; Bernard Escudier; Piotr Tomczak; Thomas E Hutson; M Dror Michaelson; Sylvie Negrier; Stephane Oudard; Martin E Gore; Jamal Tarazi; Subramanian Hariharan; Connie Chen; Brad Rosbrook; Sinil Kim; Brian I Rini
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316

Review 10.  Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials.

Authors:  James J Driscoll; Oliver Rixe
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360
View more
  1 in total

1.  Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review.

Authors:  John Sharp; Ali Raza Khaki; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2021-09-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.